Tau Protein

Tau is a microtubule-associated protein that plays a critical role in stabilizing the internal structural skeleton of neurons. In healthy neurons, tau binds to microtubules — the tracks along which nutrients and other materials are transported within cells — and helps maintain their structure and function. Normal tau is important for neuronal health.

In Alzheimer's disease and other tauopathies, tau undergoes abnormal hyperphosphorylation — too many phosphate groups are added to the protein, causing it to detach from microtubules. Once detached, hyperphosphorylated tau molecules aggregate with each other, forming paired helical filaments and ultimately the neurofibrillary tangles visible in brain tissue under a microscope. These tangles disrupt neuronal transport, damage the internal architecture of neurons, and are associated with neuronal death.

Tau pathology in Alzheimer's disease spreads through the brain in a characteristic pattern described by the Braak staging system: beginning in the entorhinal cortex and hippocampus, then spreading to the limbic system, and finally to the neocortex. This spreading pattern correlates closely with the progression of cognitive symptoms — which is why tau staging has become an important predictor of clinical disease stage.

While amyloid pathology begins earlier in Alzheimer's disease, tau pathology correlates more closely with cognitive symptoms and neuronal loss. The extent and location of tau tangles better predicts clinical cognitive status than amyloid burden alone. This is why tau PET imaging and plasma p-tau217 measurement are increasingly important in clinical evaluation and trial design.

Tau is also central to other neurodegenerative conditions beyond Alzheimer's — collectively called tauopathies — including frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy (CTE), and corticobasal degeneration. Each involves different tau isoforms, different distributions of pathology, and different clinical presentations.

Anti-tau treatments are an active area of development. Unlike the anti-amyloid antibodies that have reached approval, anti-tau approaches have so far struggled in clinical trials. Several mechanisms are being targeted: preventing tau aggregation, promoting tau clearance, and blocking tau spread between neurons. Results from later-stage trials are expected in the next several years.